Loading...



Shopping cart processing ...
0
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Menu
Customer Support 24/7
USA/Canada Toll Free USA
UK UK
AUS AU
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Currency
USD
Your cart: $0.00 (0 items)
Checkout

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!

Testimonials:

  • Chris Dutton Uxbridge, UK
    Great store, delivered on time, support is very helpful. Your pills really made my sexual life. I did expect a certain effect but never dreamed of anything like this! Thanks a lot.
More info »

Brand Premarin

Brand Premarin
Premarin is an estrogenic drug that regulates the development and maintenance of the function of the female reproductive system, the formation of female secondary sexual characteristics.

Brand: Conjugated Estrogens

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: September 2023
View product image
Package Price Per pill Save Order
Brand Premarin 0.625 mg
112 pills - 0.625 mg
+ 12 free Viagra 100 mg, 7% discount for future orders
$341.95 $3.05 $97.77 Add to cart
84 pills - 0.625 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$273.97 $3.26 $55.82 Add to cart
56 pills - 0.625 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$197.95 $3.53 $21.91 Add to cart
28 pills - 0.625 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$109.93 $3.93 No Add to cart
Brand Premarin 0.3 mg
112 pills - 0.3 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$243.99 $2.18 $123.97 Add to cart
84 pills - 0.3 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$195.97 $2.33 $80.00 Add to cart
56 pills - 0.3 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$155.95 $2.78 $28.03 Add to cart
28 pills - 0.3 mg $91.99 $3.29 No Add to cart

Product description

Pharmacological action of Premarin

Buy Premarine in Canada

Estrogenic agent, regulates the development and maintenance of the function of the female reproductive system, the formation of female secondary sexual characteristics. Once in the bloodstream, it forms a complex with a specific receptor (in the fallopian tubes, cervix, excretory ducts of the mammary glands, vagina, urethra, breast, liver, hypothalamus, pituitary gland), stimulates the synthesis of DNA and proteins. At the same time, the proliferation of the epithelium is noted, the sensitivity of the muscles of the uterus and tubes to the drugs that excite their motility increases.

Reduces bone resorption of Ca2 + during menopause, prevents the involution of the genitals. It has a hypolipidemic effect, reduces the concentration of LDL in the blood, increases HDL, sensitivity to the action of insulin, improves glucose utilization; stimulates the production of globulins by the liver that bind sex hormones, renin and blood coagulation factors; affects the exchange of Ca2 + and phosphorus (contributes to the preservation of the normal structure of bones, indirectly contributes to the formation of the skeleton and its final growth).

In large doses, it retains water and Na + in the body, inhibits erythropoiesis. Due to the participation in the implementation of positive and negative feedback in the hypothalamic-pituitary-ovarian system, the drug causes moderately pronounced central effects. Eases (eliminates) the manifestations of climacteric syndrome: a feeling of heat, increased sweating, dizziness, irritability, depression; prevents the development of postmenopausal osteoporosis. Promotes the normalization of the menstrual cycle in women. In men, it reduces the concentration of testosterone.

Indications for use Premarin

Normalizing estrogen levels with Premarin

Replacement therapy in peri - and postmenopausal women, ovarian hypofunction (primary and secondary amenorrhea, oligomenorrhea, dysmenorrhea), sexual infantilism, hypogonadism, secondary estrogen deficiency (including after oophorectomy for non-malignant diseases or after radiation castration), breast carcinoma (some inoperable forms), androgen-dependent prostate carcinoma.

Menopausal syndrome ("hot flashes" of blood to the skin of the upper half of the body, increased sweating, sleep disturbances, irritability, depression, atrophic urethritis and vaginitis), postmenopausal osteoporosis, prevention of atherosclerosis and CVD diseases in menopause.

How to use: dosage and course of treatment

Premarin packaging

Inside, the average dose for cyclic use is 0.625-1.25 mg / day for 21 days, with an interval of 7 days for all indications, with the exception of individual cases of breast carcinoma, prostate gland and prevention of lactostasis. With continuous treatment, take daily, for 1 reception.

In the presence of menstrual bleeding, treatment begins from the 5th day of the menstrual cycle, and from 15 to 21 days, an additional gestagenic drug is prescribed. With a prolonged absence of menstruation, treatment begins on any day. If necessary, on the 5-7 day of treatment, the daily dose can be increased to 3.75 mg, then it is reduced to 1.25 mg.

With intermenstrual bleeding during estrogen therapy, the dose of the latter is increased. In the next cycle, the dose that was required to stopprescribed bleeding in the previous cycle is. In subsequent cycles, the dose of estrogen is gradually reduced to maintenance.

With climacteric syndrome, it is prescribed in cycles of 1.25 mg of the drug daily. Doses are increased or decreased depending on the severity of symptoms and the patient's response.

In postmenopausal women, as replacement therapy for conditions caused by estrogen deficiency - 0.3-1.25 mg daily, in cycles.

After oophorectomy and with primary ovarian dysfunction - 1.25 mg / day continuously or in cycles.

With dysfunctional uterine bleeding - 3.75-7.5 mg / day (in divided doses). It is believed that bleeding can be stopped in 2-5 days. If it does not stop, it is recommended to increase the dose of the drug by 50% or more. In the last 5-10 days of estrogen therapy, progestin is prescribed by mouth. Bleeding should stop 2-5 days after the end of therapy.

With hypogonadism - 2.5-7.5 mg daily for 20 days, followed by a break for 10 days. If bleeding does not occur at the end of this period, similar therapy is repeated. The number of courses of estrogen therapy depends on the sensitivity of the endometrium. If bleeding occurs at the end of day 10 of the period, begin a 20-day estrogen-progestin cycle as described below (for amenorrhea).

With amenorrhea - 2.5-7.5 mg daily in divided doses for 20 days. During the last 5 days of estrogen therapy, progestogen is prescribed orally. If bleeding occurs at the end of the treatment cycle, treatment is stopped and resumed on the 5th day of bleeding.

For breast carcinoma in postmenopausal women and inoperable breast cancer in men - 10 mg 3 times a day for 3 months. For prostate carcinoma - 1.25-2.5 mg 3 times a day.

In postmenopausal osteoporosis - 0.625 mg / day cyclically, for a long time.

For the prevention of CVD diseases - 0.625-1.25 mg / day.

Elderly patients are prescribed the minimum dose that causes the effect.

Premarin: for osteoporosis, vasomotor disorders, atrophic vaginitis and urethritis, female hypogonadism and primary ovarian dysfunction - 0.625-1.25 mg / day, for the prevention of CVD diseases - 0.625 mg / day.


Special instructions

During treatment, it is necessary to remember about the risk of developingcancer endometrialin postmenopausal women.

Before starting the appointment, a thorough general medical and gynecological examination should be performed, including examination of the mammary glands and performing a vaginal Pap smear to detect malignant cells. Such studies should be carried out every 6 months of treatment.

In order to reduce the risk of hyperplasia orpatients with an intact uterus cancer, endometrialare prescribed in combination with gestagens from days 10 to 14 of the menstrual cycle. If therapy with gestagens is not performed, a gynecological examination with a mandatory endometrial biopsy is indicated.

Information about the risk of developing breast cancer in postmenopausal women during estrogen treatment is controversial. It is believed that the use of high doses or long-term therapy for more than 10 years increases the risk of developing breast cancer. However, at present, most researchers consider this fact unproven. Women receiving estrogen replacement therapy should have regular breast examinations and should be trained in breast self-examination skills.

Against the background of therapy, an increase in the existing uterine leiomyoma is possible.

There are reports of an increased risk of developing gallbladder disease in postmenopausal women taking estrogens.

Estrogens accelerate the process of epiphyseal ossification, therefore, should not be used in children and adolescents during the period of intensive growth.

The use of estrogens during pregnancy increases the risk of developing birth defects of the reproductive system in the fetus.

Treatment should be discontinued 1 month before the planned surgical intervention, during prolonged immobilization.

If thromboembolic complications occur or if their occurrence is suspected, estrogen therapy should be discontinued immediately. Patients with an increased risk of thromboembolic complications should be closely monitored.

Application during pregnancy and lactation

Contraindicated during pregnancy

Interaction

Application enhances the effect of lipid-lowering drugs.

Weakens the effects of male sex hormones, acetylcholinesterase inhibitors, indirect anticoagulants, antidepressants, diuretic, antihypertensive and hypoglycemic drugs.

The effectiveness is reduced with the appointment of barbiturates, phenytoin, phenylbutazone, butadione and rifampicin; increases - when combined with folic acid and thyroid preparations.

Contraindications

Hypersensitivity, pregnancy, estrogen-dependent malignant neoplasms or suspicion of them, unusual or undiagnosed genital or uterine bleeding, thrombophlebitis or thromboembolic diseases in the active phase (except for the treatment ofcancer breast and prostate).

With care. Thrombophlebitis, thrombosis or thromboembolism (with a history of estrogen intake); familial hyperlipoproteinemia, pancreatitis, endometriosis, a history of gallbladder disease (especially cholelithiasis), severe hepatic failure, jaundice (including a history of a previous pregnancy), hepatic porphyria, leiomyoma, hypercalcemia associated with breast cancer...

Only for the treatment of breast and prostate cancer: diseases of the coronary or cerebral vessels, active thrombophlebitis or thromboembolic diseases (high doses of estrogens used for treatment increase the risk of developing myocardial infarction, pulmonary embolism, thrombophlebitis).


Side effects

In women: soreness, sensitivity and enlargement of the mammary glands, amenorrhea, bleeding "breakthrough", menorrhagia, intermenstrual "smearing" vaginal discharge, swelling of the mammary glands, increased libido.

In men, breast tenderness and sensitivity, gynecomastia, decreased libido.

Peripheral edema, gallbladder obstruction, hepatitis, pancreatitis. Intestinal or biliary colic, flatulence, anorexia, nausea, diarrhea, dizziness, headache (including migraine), contact lens intolerance, vomiting (mainly of central origin, mainly when using large doses).

In the treatment of breast and prostate cancer (optional): thromboembolism, thrombosis.

Overdose. Symptoms: nausea, vomiting, withdrawal bleeding.

Treatment: gastric lavage, symptomatic therapy.